Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 4/2017

Open Access 01-04-2017 | Original Article

Dalbavancin reduces biofilms of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE)

Authors: D. Knafl, S. Tobudic, S. C. Cheng, D. R. Bellamy, F. Thalhammer

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 4/2017

Login to get access

Abstract

Activity of dalbavancin against methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE) in biofilm was investigated and the microbicidal biofilm concentrations (MBC) were determined. Biofilms obtained from ten MRSA and ten MRSE bloodstream isolates, collected from patients in the General Hospital of Vienna between 2012 and 2015, were incubated with dalbavancin in trypticase soy broth (TSB) in serial dilution from 0.0625 mg/l to 256 mg/l using a microtiter plate biofilm model. The plates were incubated for 24 h at 37 ° C and 50% humidity. Biofilms were fixed with 2.5% glutaraldehyde and stained with crystal violet. Subsequently the optical density (OD620) was used to measure the MBC, defined as the concentration of dalbavancin leading to a 50% reduction of biofilm. MBC for MRSA was 1 mg/l–4 mg/l (minimal inhibitory concentrations (MIC) 0.0312 mg/l–0.064 mg/l). MBC for MRSE was 2 mg/l–16 mg/l (MIC 0.023 mg/l–0.0625 mg/l). Dalbavancin successfully reduced MRSA and MRSE in biofilms, and therefore provides a promising option for the treatment of biofilm-associated infections.
Literature
1.
go back to reference Hall-Stoodley L, Costerton JW, Stoodley P (2004) Bacterial biofilms: from the natural environment to infectious diseases. Nat Rev Microbiol 2:95–108CrossRefPubMed Hall-Stoodley L, Costerton JW, Stoodley P (2004) Bacterial biofilms: from the natural environment to infectious diseases. Nat Rev Microbiol 2:95–108CrossRefPubMed
3.
go back to reference Parsek MR, Singh PK (2003) Bacterial biofilms: an emerging link to disease pathogenesis. Annu Rev Microbiol 57:677–701CrossRefPubMed Parsek MR, Singh PK (2003) Bacterial biofilms: an emerging link to disease pathogenesis. Annu Rev Microbiol 57:677–701CrossRefPubMed
4.
go back to reference Simor AE, Pelude L, Golding G (2016) Determinants of outcome in hospitalized patients with methicillin-resistant Staphylococcus aureus bloodstream infection: results from national surveillance in Canada, 2008–2012. Infect Control Hosp Epidemiol37(4):390–397CrossRefPubMed Simor AE, Pelude L, Golding G (2016) Determinants of outcome in hospitalized patients with methicillin-resistant Staphylococcus aureus bloodstream infection: results from national surveillance in Canada, 2008–2012. Infect Control Hosp Epidemiol37(4):390–397CrossRefPubMed
5.
go back to reference Zajonz D, Wuthe L, Rodloff AC et al (2015) Infections of hip and knee endoprotheses: spectrum of pathogens and the role of multiresistant bacteria. Chirurg 87(4):332–339 [Article in German] Zajonz D, Wuthe L, Rodloff AC et al (2015) Infections of hip and knee endoprotheses: spectrum of pathogens and the role of multiresistant bacteria. Chirurg 87(4):332–339 [Article in German]
6.
go back to reference Seltzer E, Dorr MB, Goldstein BP et al (2003) Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis 37:1298–1303CrossRefPubMed Seltzer E, Dorr MB, Goldstein BP et al (2003) Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis 37:1298–1303CrossRefPubMed
7.
go back to reference Baldoni D, Furustrand Tafin U, Aeppli S et al (2013) Activity of dalbavancin, alone and in combination with rifampicin, against methicillin-resistant Staphylococcus Aureus in a foreign-body infection model. Int J Antimicrob Agents 42:220–225CrossRefPubMed Baldoni D, Furustrand Tafin U, Aeppli S et al (2013) Activity of dalbavancin, alone and in combination with rifampicin, against methicillin-resistant Staphylococcus Aureus in a foreign-body infection model. Int J Antimicrob Agents 42:220–225CrossRefPubMed
8.
go back to reference Raad I, Darouiche R, Vazquez J et al (2005) Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis 40:374–380CrossRefPubMed Raad I, Darouiche R, Vazquez J et al (2005) Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis 40:374–380CrossRefPubMed
9.
go back to reference Streit JM, Fritsche TR, Sader HS et al (2004) Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn Microbiol Infect 48:137–143CrossRef Streit JM, Fritsche TR, Sader HS et al (2004) Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn Microbiol Infect 48:137–143CrossRef
10.
go back to reference Christensen GD, Simpson WA, Bisno AL et al (1982) Adherence of slime-producing strains of Staphylococcus Epidermidis to smooth surfaces. Infect Immun 37:318–326PubMedPubMedCentral Christensen GD, Simpson WA, Bisno AL et al (1982) Adherence of slime-producing strains of Staphylococcus Epidermidis to smooth surfaces. Infect Immun 37:318–326PubMedPubMedCentral
Metadata
Title
Dalbavancin reduces biofilms of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE)
Authors
D. Knafl
S. Tobudic
S. C. Cheng
D. R. Bellamy
F. Thalhammer
Publication date
01-04-2017
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 4/2017
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-016-2845-z

Other articles of this Issue 4/2017

European Journal of Clinical Microbiology & Infectious Diseases 4/2017 Go to the issue